Clinical Trial

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 20, 2025 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-center, open-label, dose-escalation study to observe the safety and efficacy of different doses of CAR-GPRC5D in patients with R/R MM or Plasma Cell Leukemia.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-02-26; most recent amendment 2025-05-15.
Status change: Not Yet Recruiting → Recruiting 2023-10-08
Trial Details
NCT Number NCT05759793
Lead Sponsor Nanjing IASO Biotechnology Co., Ltd.
Collaborators: Ruijin Hospital
Conditions Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia
Enrollment 12 participants
Start Date 2023-03-30
Primary Completion 2025-09-01 (estimated)
Study Completion 2026-10-01 (estimated)
Updated on ClinicalTrials.gov 2025-05-20